CN104098499B - The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole - Google Patents
The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole Download PDFInfo
- Publication number
- CN104098499B CN104098499B CN201310120074.4A CN201310120074A CN104098499B CN 104098499 B CN104098499 B CN 104098499B CN 201310120074 A CN201310120074 A CN 201310120074A CN 104098499 B CN104098499 B CN 104098499B
- Authority
- CN
- China
- Prior art keywords
- acid
- preparation
- reaction
- compound
- benzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- KRIJKJMYOVWRSJ-UHFFFAOYSA-N 3-methyl-5-phenylmethoxy-2-(4-phenylmethoxyphenyl)-1h-indole Chemical compound C1=C2C(C)=C(C=3C=CC(OCC=4C=CC=CC=4)=CC=3)NC2=CC=C1OCC1=CC=CC=C1 KRIJKJMYOVWRSJ-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 238000005589 Bischler-Moehlau reaction Methods 0.000 claims abstract description 13
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 11
- 238000006482 condensation reaction Methods 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 7
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 6
- 239000007848 Bronsted acid Substances 0.000 claims abstract 4
- 239000000376 reactant Substances 0.000 claims abstract 4
- 239000003513 alkali Substances 0.000 claims abstract 3
- 150000001298 alcohols Chemical class 0.000 claims abstract 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical group [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 150000007529 inorganic bases Chemical class 0.000 claims description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 150000002475 indoles Chemical class 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229940072033 potash Drugs 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 235000015320 potassium carbonate Nutrition 0.000 claims 1
- 229960005137 succinic acid Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 125000001041 indolyl group Chemical group 0.000 abstract description 4
- 238000005580 one pot reaction Methods 0.000 abstract description 4
- 238000007867 post-reaction treatment Methods 0.000 abstract description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 26
- -1 2-bromo-(4-benzyloxyphenyl) acetone Chemical compound 0.000 description 14
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 12
- KQBDLOVXZHOAJI-UHFFFAOYSA-N (4-phenylmethoxyphenyl)azanium;chloride Chemical compound Cl.C1=CC(N)=CC=C1OCC1=CC=CC=C1 KQBDLOVXZHOAJI-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 6
- 0 Cc(c1c2)c(-c3ccc(*)cc3)[n](Cc3ccc(C)cc3)c1ccc2OCc1ccccc1 Chemical compound Cc(c1c2)c(-c3ccc(*)cc3)[n](Cc3ccc(C)cc3)c1ccc2OCc1ccccc1 0.000 description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 229960004622 raloxifene Drugs 0.000 description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960000817 bazedoxifene Drugs 0.000 description 2
- 229960003713 bazedoxifene acetate Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000007039 two-step reaction Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FIIDVVUUWRJXLF-UHFFFAOYSA-N 4-phenylmethoxyaniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC=C1 FIIDVVUUWRJXLF-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OPAKTFZZLFDZMZ-UHFFFAOYSA-N CC(C(C(C#CC1)=CC=C1OCc1ccccc1)=O)Br Chemical compound CC(C(C(C#CC1)=CC=C1OCc1ccccc1)=O)Br OPAKTFZZLFDZMZ-UHFFFAOYSA-N 0.000 description 1
- LAOHJLHFQSYRBG-UHFFFAOYSA-N CC(C(c(cc1)ccc1OCc1ccccc1)=O)Nc(cc1)ccc1OCc1ccccc1 Chemical compound CC(C(c(cc1)ccc1OCc1ccccc1)=O)Nc(cc1)ccc1OCc1ccccc1 LAOHJLHFQSYRBG-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备方法。The invention relates to a preparation method of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole.
背景技术Background technique
由Wyeth公司研制的巴多昔芬(bazedoxifene)是新一代SERM(选择性雌激素受体调节剂),它可以竞争性地抑制17β-雌二醇与ERα和ERβ的结合,单独使用对人乳癌细胞系无激动剂活性。临床前试验显示,在同类产品中,它在改善子宫特性方面比雷洛昔芬(第二代SERM)和拉索昔芬(第三代SERM)更具优势,另外,血管舒缩不稳定模型试验显示,它对中枢神经系统副作用很小,在激活肝脂酶启动子方面,它为一种相对有效的激动剂,而雷洛昔芬则无效,当与雷洛昔芬联用时,它能够抑制雷洛昔芬对啮齿类动物子宫的刺激作用,可见二者对子宫的效应是不同的。临床前试验数据表明,它比目前所知的其他SERMs更具靶向活性,是至今“同类产品中之最佳”。该药目前已于2009年在欧盟(商品名:Conbriza)和日本(商品名:Viviant)上市。其首要适应症为治疗和预防绝经期妇女的骨质疏松症。Bazedoxifene, developed by Wyeth, is a new generation of SERM (selective estrogen receptor modulator), which can competitively inhibit the binding of 17β-estradiol to ERα and ERβ, and is used alone for human breast cancer The cell line has no agonist activity. Preclinical tests show that it is superior to raloxifene (second generation SERM) and lasofoxifene (third generation SERM) in improving uterine properties among similar products, and the vasomotor instability model Tests have shown that it has little side effects on the central nervous system, and it is a relatively effective agonist in activating the hepatic lipase promoter, while raloxifene is ineffective. When combined with raloxifene, it can Inhibiting the stimulating effect of raloxifene on the uterus of rodents, it can be seen that the effects of the two on the uterus are different. Preclinical test data show that it has more targeted activity than other SERMs known so far, and it is the "best of its kind" so far. The drug has been launched in the European Union (trade name: Conbriza) and Japan (trade name: Viviant) in 2009. Its primary indication is the treatment and prevention of osteoporosis in postmenopausal women.
醋酸巴多昔芬(Bazedoxifeneacetate)化学名为1-{4-[2-(环己亚胺基-1-)乙氧基]苄基}-2-(4-羟基苯基)-3-甲基-1H-吲哚-5-酚醋酸盐,其制备方法如下:The chemical name of bazedoxifene acetate is 1-{4-[2-(cyclohexylimino-1-)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methanol Base-1H-indole-5-phenol acetate, its preparation method is as follows:
5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)是合成醋酸巴多昔芬的关键中间体,其合成主要有以下三种方法:5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I) is a key intermediate in the synthesis of bazedoxifene acetate, and its synthesis mainly has the following three methods :
路线一(US5998402):Route 1 (US5998402):
该路线以2-溴-(4-苄氧基苯基)丙酮(II)、对苄氧基苯胺盐酸盐(III)为起始原料,以DMF为溶剂,回流反应,II与III缩合得5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)。在此反应中,对苄氧基苯胺盐酸盐(III)的用量是2-溴-(4-苄氧基苯基)丙酮(II)的3.5倍(摩尔量比),有大量的对苄氧基苯胺盐酸盐(III)剩余,既给后处理带来了麻烦,需要柱层析纯化,又浪费了原料,且收率低(33%),不适合工业化生产。The route uses 2-bromo-(4-benzyloxyphenyl) acetone (II) and p-benzyloxyaniline hydrochloride (III) as starting materials, DMF as solvent, reflux reaction, and condensation of II and III to obtain 5-Benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I). In this reaction, the consumption of p-benzyloxyaniline hydrochloride (III) is 3.5 times (molar ratio) of 2-bromo-(4-benzyloxyphenyl) acetone (II), there is a large amount of p-benzyloxyaniline Oxyaniline hydrochloride (III) remains, which not only brings trouble to post-processing, requires column chromatography purification, but also wastes raw materials, and the yield is low (33%), which is not suitable for industrial production.
路线二(US5998402):Route 2 (US5998402):
该路线以路线一为基础,同样以2-溴-(4-苄氧基苯基)丙酮(II)、对苄氧基苯胺盐酸盐(III)为起始原料,以DMF为溶剂,II与III缩合得5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)。不同的是,该路线中两步反应合并为“一锅”反应:第一步中加入三乙胺作碱,II与1.3倍摩尔量的III缩合得中间产物1-(4-苄氧基苯基)-2-[(4-苄氧基苯基)氨基]丙酮(IV),IV不经分离,与再次加入的1.5倍摩尔量的III发生Bischler-Mohlau吲哚关环反应生成产物I。该路线虽然将两步反应合并为“一锅”,简化了反应操作,但为了除去过量的III和杂质,后处理步骤繁琐,所得固体粗品需在甲醇/乙醚中多次打浆洗涤才能得到较纯的产物I,收率较低(55%)。This route is based on route 1, also using 2-bromo-(4-benzyloxyphenyl) acetone (II) and p-benzyloxyaniline hydrochloride (III) as starting materials, using DMF as solvent, II Condensation with III gives 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I). The difference is that the two-step reactions in this route are combined into a "one-pot" reaction: in the first step, triethylamine is added as a base, and II is condensed with 1.3 times the molar amount of III to obtain the intermediate product 1-(4-benzyloxybenzene Base)-2-[(4-benzyloxyphenyl)amino]acetone (IV), IV was not separated, and the Bischler-Mohlau indole ring closure reaction with 1.5 times molar amount of III was added again to generate product I. Although this route combines the two-step reactions into "one pot", which simplifies the reaction operation, in order to remove excess III and impurities, the post-treatment steps are cumbersome, and the obtained solid crude product needs to be beaten and washed in methanol/ether several times to obtain a relatively pure product. The product I, the yield is lower (55%).
路线三(WO2008098527):Route 3 (WO2008098527):
该路线以2-溴-(4-苄氧基苯基)丙酮(II)、对苄氧基苯胺盐酸盐(III)为起始原料(对苄氧基苯胺盐酸盐(III)的用量是2-溴-(4-苄氧基苯基)丙酮(II)的1.1-1.2倍),以醇(乙醇、异丙醇等)作溶剂,缩合得中间体1-(4-苄氧基苯基)-2-[(4-苄氧基苯基)氨基]丙酮(IV),将IV分离纯化后,IV再与0.2倍摩尔量的III发生Bischler-Mohlau吲哚关环反应得产物I。该路线收率较高(两步总收率60%-75%),但中间产物IV需分离纯化,增加了反应操作,整条路线不够简洁。This route takes 2-bromo-(4-benzyloxyphenyl) acetone (II) and p-benzyloxyaniline hydrochloride (III) as starting materials (the amount of p-benzyloxyaniline hydrochloride (III) 1.1-1.2 times that of 2-bromo-(4-benzyloxyphenyl) acetone (II), use alcohol (ethanol, isopropanol, etc.) as solvent, and condense to obtain the intermediate 1-(4-benzyloxy Phenyl)-2-[(4-benzyloxyphenyl)amino]acetone (IV), after separating and purifying IV, Bischler-Mohlau indole ring-closing reaction occurs between IV and 0.2 times molar amount of III to obtain product I . The yield of this route is relatively high (the total yield of two steps is 60%-75%), but the intermediate product IV needs to be separated and purified, which increases the reaction operation, and the whole route is not concise enough.
发明内容Contents of the invention
本发明所解决的技术问题在于为了克服现有的5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备工艺复杂、操作繁琐、产率低等缺陷,提供了一种5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备方法。该制备方法操作简单,成本低,大大简化了反应后处理过程,且纯度高,反应收率高,适于放大生产。The technical problem solved by the present invention is in order to overcome the complex preparation process of the existing 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole, complicated operation and low yield With low defects, a preparation method of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole is provided. The preparation method is simple in operation, low in cost, greatly simplifies the post-reaction treatment process, has high purity and high reaction yield, and is suitable for scale-up production.
本发明是通过以下技术方案解决上述技术问题的:The present invention solves the above technical problems through the following technical solutions:
本发明提供了5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚的制备方法,其包括下列步骤:The invention provides a preparation method of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole, which comprises the following steps:
(1)在醇类溶剂中,在碱的作用下,将化合物II与化合物III进行缩合反应;(1) In an alcoholic solvent, under the action of a base, conduct a condensation reaction between compound II and compound III;
(2)将步骤(1)的反应液与质子酸混合,进行Bischler-Mohlau吲哚关环反应,即可;(2) Mix the reaction liquid of step (1) with protonic acid, and carry out the Bischler-Mohlau indole ring-closing reaction;
步骤(1)中,所述的醇类溶剂较佳地为正丁醇、异丁醇、正丙醇、异丙醇和乙醇中的一种或多种;更佳地为正丁醇、异丁醇和正丙醇中的一种或多种。所述的醇类溶剂与化合物II的体积质量比较佳地为5~15ml/g。In step (1), the alcohol solvent is preferably one or more of n-butanol, isobutanol, n-propanol, isopropanol and ethanol; more preferably n-butanol, isobutanol One or more of alcohol and n-propanol. The volume mass of the alcohol solvent and compound II is preferably 5-15ml/g.
步骤(1)中,所述的碱较佳地为无机碱和/或有机碱。所述的无机碱较佳地为碳酸钾、碳酸钠、碳酸氢钠、碳酸氢钾、氢氧化钠和氢氧化钾中的一种或多种;所述的有机碱较佳地为三乙胺、吡啶、4-二甲基氨基吡啶、吗啉和N,N-二异丙基乙胺中的一种或多种。所述的碱更佳地为三乙胺。所述的碱与化合物II的摩尔比较佳地为(2:1)~(2.5:1)。In step (1), the base is preferably an inorganic base and/or an organic base. Described inorganic base is preferably one or more in potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide and potassium hydroxide; Described organic base is preferably triethylamine One or more of , pyridine, 4-dimethylaminopyridine, morpholine and N,N-diisopropylethylamine. The base is more preferably triethylamine. The molar ratio of the base to compound II is preferably (2:1)-(2.5:1).
步骤(1)中,所述的化合物II与化合物III的摩尔比较佳地为(1:1)~(1:1.2)。In step (1), the molar ratio of compound II to compound III is preferably (1:1)-(1:1.2).
步骤(1)中,所述的缩合反应的温度较佳地为75~160℃,更佳地为100~130℃。所述的缩合反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,一般以化合物II消失时作为反应的终点,所述的缩合反应的时间较佳地为2~4小时。In step (1), the temperature of the condensation reaction is preferably 75-160°C, more preferably 100-130°C. The progress of the condensation reaction can be monitored by conventional means in the art (such as TLC or HPLC). Generally, the end point of the reaction is when the compound II disappears. The condensation reaction time is preferably 2-4 hours.
本发明中,所述的步骤(1)得到的反应液可不经后处理直接进行步骤(2)。In the present invention, the reaction solution obtained in step (1) can be directly carried out in step (2) without post-treatment.
步骤(2)中,在将步骤(1)的反应液与质子酸混合之前较佳地进行冷却。所述的冷却较佳地为自然冷却至所述的步骤(1)的反应液的温度为10~30℃。In step (2), cooling is preferably performed before mixing the reaction solution in step (1) with the protonic acid. The cooling is preferably natural cooling until the temperature of the reaction liquid in the step (1) is 10-30°C.
步骤(2)中,所述的质子酸较佳地为无机酸和/或有机酸。所述的无机酸较佳地为盐酸、硫酸和磷酸中的一种或多种,更佳地为盐酸;所述的有机酸较佳地为甲酸、乙酸、丙酸、草酸、富马酸、马来酸、琥珀酸、酒石酸、柠檬酸、丙二酸、甲磺酸、苯磺酸、对甲苯磺酸和对甲苯磺酸一水合物中的一种或多种,更佳地为对甲苯磺酸。所述的质子酸与化合物II的摩尔比较佳地为(0.05:1)~(0.3:1)。In step (2), the protic acid is preferably an inorganic acid and/or an organic acid. Described inorganic acid is preferably one or more in hydrochloric acid, sulfuric acid and phosphoric acid, is more preferably hydrochloric acid; Described organic acid is preferably formic acid, acetic acid, propionic acid, oxalic acid, fumaric acid, One or more of maleic acid, succinic acid, tartaric acid, citric acid, malonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and p-toluenesulfonic acid monohydrate, more preferably p-toluene sulfonic acid. The molar ratio of the protonic acid to compound II is preferably (0.05:1)-(0.3:1).
步骤(2)中,所述的Bischler-Mohlau吲哚关环反应的温度较佳地为75~160℃,更佳地为100~130℃。In step (2), the temperature of the Bischler-Mohlau indole ring closure reaction is preferably 75-160°C, more preferably 100-130°C.
所述的Bischler-Mohlau吲哚关环反应的进程可通过本领域常规手段(如TLC或HPLC)进行监测,所述的Bischler-Mohlau吲哚关环反应的时间较佳地为5~15小时。The progress of the Bischler-Mohlau indole ring-closing reaction can be monitored by conventional means in the art (such as TLC or HPLC), and the time of the Bischler-Mohlau indole ring-closing reaction is preferably 5-15 hours.
其中,所述的Bischler-Mohlau吲哚关环反应结束后还可以进行后处理,进一步纯化化合物I。所述的后处理的方式可为本领域常规的后处理方式,优选包括如下步骤:抽滤,干燥,即可。当所述的碱采用无机碱时,抽滤后较佳地进行水洗,再干燥。Wherein, after the completion of the Bischler-Mohlau indole ring-closing reaction, post-treatment can be carried out to further purify compound I. The post-treatment method can be a conventional post-treatment method in the art, preferably including the following steps: suction filtration and drying. When the base is an inorganic base, it is preferably washed with water after suction filtration, and then dried.
在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。On the basis of not violating common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain preferred examples of the present invention.
本发明所用试剂和原料均市售可得。The reagents and raw materials used in the present invention are all commercially available.
本发明的积极进步效果在于:本发明的合成路线与原有技术相比较,将第一步缩合反应与第二步Bischler-Mohlau吲哚关环反应合并为“一锅”反应,操作简便;反应液中加入酸,无需再次加入原料化合物III,简化了操作,节省了成本;反应产物I直接从反应溶剂中析出,大大简化了反应后处理过程,且纯度高,反应收率高,适于放大生产。The positive progress effect of the present invention is: the synthetic route of the present invention compares with prior art, and the first step condensation reaction and the second step Bischler-Mohlau indole ring-closing reaction are merged into "one pot" reaction, easy and simple to operate; Reaction Adding acid into the solution does not need to add the raw material compound III again, which simplifies the operation and saves the cost; the reaction product I is directly precipitated from the reaction solvent, which greatly simplifies the post-reaction treatment process, and has high purity and high reaction yield, which is suitable for scale-up Production.
具体实施方式detailed description
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。The present invention is further illustrated below by means of examples, but the present invention is not limited to the scope of the examples. For the experimental methods that do not specify specific conditions in the following examples, select according to conventional methods and conditions, or according to the product instructions.
实施例1Example 1
合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)
2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至正丁醇(120ml)中,加入三乙胺(12.2ml),升温至118℃回流,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入浓盐酸(1.0ml),升温至118℃继续反应7小时。反应液冷却,抽滤,干燥得白色固体15.2g,HPLC纯度:98%,收率90.5%。Add 2-bromo-(4-benzyloxyphenyl) acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to n-butanol (120ml), add triethyl Amine (12.2ml) was heated to 118°C and refluxed. After 3 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; concentrated hydrochloric acid (1.0ml) was added, and the temperature was raised to 118°C to continue the reaction for 7 hours. The reaction liquid was cooled, filtered with suction, and dried to obtain 15.2 g of white solid, HPLC purity: 98%, yield 90.5%.
1H-NMR(400MHz,d6-DMSO)δ(ppm):7.798(brs,1H,-NH-),7.102-7.557(m,14H,Ar-H),7.255(d,1H,J=2.4Hz,Ar-H),7.174(d,1H,J=4.0Hz,Ar-H),6.978(dd,1H,J=4.0Hz,2.4Hz,Ar-H),5.192(s,2H,-OCH2-),5.153(s,2H,-OCH2-),2.436(s,3H,-CH3)MS(m/z):420(M+1) 1 H-NMR(400MHz,d 6 -DMSO)δ(ppm):7.798(brs,1H,-NH-),7.102-7.557(m,14H,Ar-H),7.255(d,1H,J=2.4 Hz,Ar-H),7.174(d,1H,J=4.0Hz,Ar-H),6.978(dd,1H,J=4.0Hz,2.4Hz,Ar-H),5.192(s,2H,-OCH 2 -),5.153(s,2H,-OCH 2 -),2.436(s,3H,-CH 3 )MS(m/z):420(M+1)
实施例2Example 2
合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)
2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至异丁醇(120ml)中,加入三乙胺(12.2ml),升温至107℃回流,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入对甲苯磺酸一水合物(1.7g),升温至107℃继续反应14小时。反应液冷却,抽滤,干燥得棕褐色固体14.4g,HPLC纯度:97%,收率86%。Add 2-bromo-(4-benzyloxyphenyl) acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to isobutanol (120ml), add triethyl Amine (12.2ml), heated to 107°C and refluxed, 2-bromo-(4-benzyloxyphenyl)acetone reacted completely after 3 hours; added p-toluenesulfonic acid monohydrate (1.7g), heated to 107°C The reaction was continued for 14 hours. The reaction solution was cooled, filtered with suction, and dried to obtain 14.4 g of a tan solid, with an HPLC purity of 97% and a yield of 86%.
实施例3Example 3
合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)
2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至异丙醇(120ml)中,加入吡啶(7.1ml),升温至84℃,4小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入乙酸(0.7ml)继续反应15小时。反应液冷却,抽滤,干燥得白色固体14.6g,HPLC纯度:96%,收率87%。Add 2-bromo-(4-benzyloxyphenyl) acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to isopropanol (120ml), add pyridine ( 7.1ml), the temperature was raised to 84°C, and after 4 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; acetic acid (0.7ml) was added to continue the reaction for 15 hours. The reaction solution was cooled, filtered with suction, and dried to obtain 14.6 g of white solid, HPLC purity: 96%, yield 87%.
实施例4Example 4
合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)
2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至正丁醇(120ml)中,加入吗啉(7.7ml),升温至118℃,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入浓硫酸(0.6ml),继续反应7小时。反应液冷却,抽滤,干燥得白色固体14.7g,HPLC纯度:98%,收率88%。Add 2-bromo-(4-benzyloxyphenyl)acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to n-butanol (120ml), add morpholine (7.7ml), the temperature was raised to 118°C, and after 3 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; concentrated sulfuric acid (0.6ml) was added, and the reaction was continued for 7 hours. The reaction solution was cooled, filtered with suction, and dried to obtain 14.7 g of white solid, HPLC purity: 98%, yield 88%.
实施例5Example 5
合成5-苄氧基-2-(4-苄氧基苯基)-3-甲基-1H-吲哚(I)Synthesis of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1H-indole (I)
2-溴-(4-苄氧基苯基)丙酮(12.7g,0.04mol)、对苄氧基苯胺盐酸盐(11.1g,0.047mol)加至正丁醇(120ml)中,加入碳酸钠(9.3g),升温至118℃回流,3小时后,2-溴-(4-苄氧基苯基)丙酮反应完全;加入浓盐酸(1.0ml),升温至118℃继续反应7小时。反应液冷却,抽滤,所得固体水洗(60ml),过滤,干燥得白色固体14.8g,HPLC纯度:99%,收率88%。Add 2-bromo-(4-benzyloxyphenyl)acetone (12.7g, 0.04mol), p-benzyloxyaniline hydrochloride (11.1g, 0.047mol) to n-butanol (120ml), add sodium carbonate (9.3g), heated to 118°C and refluxed. After 3 hours, the reaction of 2-bromo-(4-benzyloxyphenyl)acetone was complete; concentrated hydrochloric acid (1.0ml) was added, and the temperature was raised to 118°C to continue the reaction for 7 hours. The reaction solution was cooled, filtered with suction, the obtained solid was washed with water (60ml), filtered, and dried to obtain 14.8g of white solid, HPLC purity: 99%, yield 88%.
Claims (10)
- The preparation method of 1.5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole, is characterized in that,It comprises the following steps:(1), in alcohols solvent, under the effect of alkali, Compound I I and compound III are carried out to condensationReaction;(2) reactant liquor of step (1) is mixed with Bronsted acid, carry out Bischler-Mohlau indoles passRing reaction;
- 2. preparation method as claimed in claim 1, is characterized in that, in step (1), describedAlcohols solvent is one or more in n-butanol, isobutanol, normal propyl alcohol, isopropyl alcohol and ethanol; DescribedAlcohols solvent be 5~15ml/g with the volume mass ratio of Compound I I.
- 3. preparation method as claimed in claim 1, is characterized in that, in step (1), describedAlkali is inorganic base and/or organic base, and described inorganic base is potash, sodium carbonate, sodium acid carbonate, carbonic acidOne or more in hydrogen potassium, NaOH and potassium hydroxide, described organic base be triethylamine, pyridine,One or more in 4-dimethylaminopyridine, morpholine and DIPEA.
- 4. preparation method as claimed in claim 1, is characterized in that, described alkali and Compound I IMol ratio be (2:1)~(2.5:1).
- 5. preparation method as claimed in claim 1, is characterized in that, in step (1), describedThe mol ratio of Compound I I and compound III is (1:1)~(1:1.2).
- 6. preparation method as claimed in claim 1, is characterized in that, in step (1), describedThe temperature of condensation reaction is 75~160 DEG C; In step (2), described Bischler-Mohlau indoles closesThe temperature of ring reaction is 75~160 DEG C.
- 7. preparation method as claimed in claim 6, is characterized in that, in step (1), describedThe temperature of condensation reaction is 100~130 DEG C; In step (2), described Bischler-Mohlau indolesThe temperature of ring closure reaction is 100~130 DEG C.
- 8. preparation method as claimed in claim 1, is characterized in that, in step (2), will walkSuddenly the reactant liquor of (1) carries out before mixing with Bronsted acid coolingly, and described being cooled to naturally cools to instituteThe temperature of the reactant liquor of the step (1) of stating is 10~30 DEG C.
- 9. preparation method as claimed in claim 1, is characterized in that, in step (2), describedBronsted acid is inorganic acid and/or organic acid; Described inorganic acid be a kind of in hydrochloric acid, sulfuric acid and phosphoric acid orMultiple; Described organic acid be formic acid, acetic acid, propionic acid, oxalic acid, fumaric acid, maleic acid, butanedioic acid,Tartaric acid, citric acid, malonic acid, methanesulfonic acid, benzene sulfonic acid, p-methyl benzenesulfonic acid and p-methyl benzenesulfonic acid one waterOne or more in compound.
- 10. preparation method as claimed in claim 1, is characterized in that, described Bronsted acid and chemical combinationThe mol ratio of thing II is (0.05:1)~(0.3:1).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310120074.4A CN104098499B (en) | 2013-04-08 | 2013-04-08 | The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310120074.4A CN104098499B (en) | 2013-04-08 | 2013-04-08 | The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104098499A CN104098499A (en) | 2014-10-15 |
CN104098499B true CN104098499B (en) | 2016-05-04 |
Family
ID=51667085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310120074.4A Active CN104098499B (en) | 2013-04-08 | 2013-04-08 | The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104098499B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800006562A1 (en) * | 2018-06-21 | 2019-12-21 | PROCEDURE AND USEFUL INTERMEDIATES FOR THE PREPARATION OF INDOLES |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
CN1309637A (en) * | 1998-05-15 | 2001-08-22 | 美国家用产品公司 | Compositions comprising 2-phenyl-indole compounds and estrogen formutations |
WO2004099139A1 (en) * | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
WO2008098527A1 (en) * | 2007-02-12 | 2008-08-21 | Zentiva A.S. | Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4187441B2 (en) * | 1999-09-17 | 2008-11-26 | ベイラー・ユニバーシテイ | Indole-containing and combretastatin-related antimitotic and antitubulin polymerization drugs |
-
2013
- 2013-04-08 CN CN201310120074.4A patent/CN104098499B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
CN1309637A (en) * | 1998-05-15 | 2001-08-22 | 美国家用产品公司 | Compositions comprising 2-phenyl-indole compounds and estrogen formutations |
WO2004099139A1 (en) * | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
WO2008098527A1 (en) * | 2007-02-12 | 2008-08-21 | Zentiva A.S. | Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole |
Non-Patent Citations (3)
Title |
---|
cient one-pot synthesis of indoles.《Tetrahedron Letters》.2007,第49卷全文. * |
Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens;Chris P.Miller等;《J.Med.Chem.》;20010425;第44卷(第11期);第1654-1657页 * |
George Bratulescu.A new and effi * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800006562A1 (en) * | 2018-06-21 | 2019-12-21 | PROCEDURE AND USEFUL INTERMEDIATES FOR THE PREPARATION OF INDOLES |
Also Published As
Publication number | Publication date |
---|---|
CN104098499A (en) | 2014-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101808792B1 (en) | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate | |
JP2013504563A (en) | Process for the preparation of indoline derivatives and intermediates thereof | |
CN103339116B (en) | Replace n-valeramide compounds, Preparation Method And The Use | |
JP2013531054A (en) | Method for preparing aminobenzoylbenzofuran derivatives | |
JP7339946B2 (en) | Method for producing 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole and hydrogen sulfate thereof | |
CN102120739A (en) | Preparation method of fasudil hydrochloride | |
CN105693603B (en) | The maleic acid datro preparation process of improvement | |
CN107698538B (en) | Preparation method of intermediate 3- (1-piperidinylmethyl) phenol of roxatidine acetate hydrochloride | |
CN112062767A (en) | Preparation method and intermediate of rumepilone | |
CN104098499B (en) | The preparation method of 5-benzyloxy-2-(4-benzyloxy phenyl)-3-Methyl-1H-indole | |
CA2756234C (en) | Synthesis of 3-{[(2r)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1h-indole | |
CN101481333B (en) | Novel rivastigmine preparation | |
CN107935866B (en) | Preparation method of dapoxetine hydrochloride impurity | |
ES2431359T3 (en) | New procedure for the preparation of Eletriptan | |
CN101481335B (en) | Rivastigmine intermediate preparation | |
US20160304452A1 (en) | Method for preparing silodosin and intermediate thereof | |
JP2015038053A (en) | Method for producing 4-(2-methyl-1-imidazolyl)-2,2-phenylbutane amide | |
ES2436027T3 (en) | Procedure for the preparation of almotriptane | |
WO2008072257A2 (en) | Process for the preparation of indole derivatives | |
CN111499528A (en) | Terbutaline sulfate intermediate, preparation method thereof and method for preparing terbutaline sulfate by using terbutaline sulfate intermediate | |
CN106554254A (en) | A kind of synthetic method of 2,3 ', 4,5 ' tetrahydroxy bibenzyl of natural product | |
CN101514167A (en) | Method for preparing chiral baclofen | |
JP2016511761A (en) | Method for synthesizing 4-piperidin-4-yl-benzene-1,3-diol and salts thereof, and novel compound tert-butyl 4- (2,4-dihydroxy-phenyl) -4-hydroxy-piperidine-1-carboxylate | |
CN100432052C (en) | Synthetic method for methoxy indole | |
WO2013001511A1 (en) | Novel salt intermediates for the synthesis of bazedoxifene acetate and process thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Pan Inventor after: Yuan Zhedong Inventor after: Liu Xiangkui Inventor after: Kong Rui Inventor after: Gu Hongmei Inventor after: Wang Xiangjian Inventor before: Chen Pan Inventor before: Yuan Zhedong Inventor before: Liu Xiangkui Inventor before: Kong Rui |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160413 Address after: 200040 Beijing West Road, Shanghai, No. 1320, No. Applicant after: Shanghai Institute of pharmaceutical industry Applicant after: China State Institute of Pharmaceutical Industry Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 200040 Beijing West Road, Shanghai, No. 1320, No. Applicant before: Shanghai Institute of pharmaceutical industry Applicant before: China State Institute of Pharmaceutical Industry |